MRC receives R100-m boost
DURBAN – The Medical Research Council of South Africa has received more than R100 million over five years to establish two new research units for the study of HIV/AIDS prevention strategies and vaccines.
The United States National Institutes for Health made the grant yesterday (wed) in response to an application by Dr Salim S. Abdool Karim, director of HIV Prevention and Vaccine Research at the MRC. It is the biggest grant ever made to a research organisation in South Africa.
The funds will be divided between an HIV Vaccine Trial Unit and an HIV Prevention Trial Unit. “Both units will ensure that South Africa stays at the forefront of the global effort to devise and test HIV vaccines and prevention strategies,” said Dr Abdool Karim.
The HIV Vaccine Trial Unit includes several international collaborative partners: Columbia University in New York (where Dr Abdool Karim is also the Professor in Clinical Public Health), the Aaron Diamond AIDS Research Centre and the New York Blood Centre, as well as local collaborators.
The HIV Prevention Trial Unit involves collaboration with the University of Natal and Columbia University.
The Vaccine Trial Unit will conduct a Phase II trial of an HIV vaccine that uses the canarypox vector. The HIV Prevention Trials Unit will conduct at least two trials in its first year — a microbicide trial and a phase III trial to assess whether Nevirapine administered to the baby can prevent HIV transmission through breast-feeding. – Health-e News Service
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
MRC receives R100-m boost
by Ali Karriem, Health-e News
July 13, 2000